Browsing category:

Hormonal Agent


Polycystic Ovarian Syndrome

Cetrorelix CAS No: 120287-85-6 Cetrorelix is traditionally used as fertility API that binds to a hormone receptor to stop gonadotropin secretion. While it may be associated with women undergoing ovarian stimulation, it appears as though there’s more to this API that meets the eye. This synthetic decapeptide is being studied to help with a variety of conditions, including the[…]

Read More

Octreotide Acetate

Octreotide Acetate CAS #: 79517-01-04 Octreotide Acetate is prescribed for a variety of GI issues, mainly for severe diarrhea brought upon by carcinoid symptoms. Its designed to imitate the natural growth-hormone inhibitor in the body, which makes it easier for the endocrine system to do its job. This API limits the excess release of glucagon secretion and insulin, making[…]

Read More

As the leading cause of blindness in the United States Diabetic Macular Edema {DME} is a serious concern for the growing aging population, affecting roughly one million Americans. The recent announcement from pSivida Corp. regarding the marketing authorization in the EU of their DME treatment Fluocinolone is hopeful for U.S. supporters of this formidable drug.[…]

Read More

The biopharmaceutical company Rockwell Medical is anxiously awaiting approval from the FDA for its injectable Vitamin D drug, Calcitriol CAS# 32222-06-3. This promising new indication approval was submitted in April of 2013, with the goal of better managing hypocalcemia in patients who experience chronic renal dialysis. As an active injectable treatment known as the brand[…]

Read More

In mid-November 2013 the FDA announced their recommendation for the approval of Tasimelteon for the treatment of non-24-disorder. This rare condition, which primarily affects the blind, occurs when the body’s biological clock does not work properly. Patients who are blind and experience this frustrating type of insomnia can now find relief, as Tasimelteon effectively resets[…]

Read More

Exciting results were revealed in Mid-March of 2013 when the REMINDER trial touted the success of Eplerenone for treating acute ST-Segment Elevation Myocardial Infarction, also known as STEMI. The results from this study were presented at the 62nd Annual Scientific Session of the American College of Cardiology, by Pfizer, who markets Inspra which is the[…]

Read More

Ethinyl Estradiol CAS# 57-63-6 Ethinyl Estradiol, CAS number 57-63-6 and Norgestimate, CAS number 35189-28-7, are both integral components in the blockbuster birth control pill Ortho Tri-Cyclen Lo. Mylan and Janssen, who market Ortho Tri-Cyclen Lo, reported an astounding 425.5 million dollars in sales for the United States for the 2012 year. With the patent for[…]

Read More

Testosterone CAS# 58-22-0, made the pharmaceutical headlines mid June 2013 when study findings were announced touting testosterone for perceived pain relief. Data presented on June 17, 2013, at the Endocrine Society’s 95th Annual Meeting offered positive results regarding the use of testosterone to improve pain tolerance. The study funded by Abbott Pharmaceuticals, involved 84 men who[…]

Read More

On October 3, 2013 the FDA approved the new medication Duavee, comprised of Bazedoxifene and conjugated estrogens (Premarin) to treat hot flashes in postmenopausal women. The unique ability of this novel treatment to curtail hot flashes and help prevent osteoporosis is encouraging for gynecologists and their female patients who are experiencing post-menopause. The combination of[…]

Read More